FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer.On April 7, 2021, the Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.
Are you looking for or in search of FDA approved “sacituzumab govitecan-hziy for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of sacituzumab govitecan-hziy injection, get in touch with our healthcare professional.
Sacituzumab govitecan (Trodelvy): In the case of this ADC, the monoclonal antibody part attaches to the Trop-2 protein on breast cancer cells and brings a chemo drug, similar to irinotecan, directly to them. (Some breast cancer cells have too much Trop-2, which helps them grow and spread quickly.)
This antibody-drug conjugate can be used by itself to treat advanced TNBC, after at least 2 other chemo regimens have been tried. This drug is given in a vein (IV) weekly for 2 weeks, followed by one week off, then restarted.
sacituzumab govitecan-hziy for injection
Contact No.
Call us
+91 11 4350 7259
Emergency Contact
+91 93139 48015
Address
Visit us anytime
F-90/1 , Okhla Industrial Area,
Phase -1 , New Delhi. India
Send us an email
medicanthealthcare@outlook.com
info@medicanthealthcare.com